Collectively, these findings demonstrate that pharmacological inhibition of DHHC9 by either Treprostinil or 10‐HCPT effectively suppresses colon cancer metastasis in vivo without compromising systemic health or primary tumour growth, providing compelling preclinical support for targeting the DHHC9‐STRN4‐YAP axis to limit adenocarcinoma dissemination. Here, STRN4 is linked to neoplasm.